{"submissions":[{"id":"ff69c47d-1c00-4e0a-8e03-39e83feca4f7","wallet":"6bB9cERcfHMzuyGwDgc3vJrk3hxoCRg4ubUP6MrMPfY3","missionId":"research","epochId":1491820,"title":"Peer Review: Screening: PMID 41062831 Trastuzumab deruxtecan in HER2-low metastatic breast ca","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [337b8a56-d71e-496d-a8e9-6e0d520a6c4c]: 'Screening: PMID 41062831 Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term surv'. Review Dimension: Clinical Safety & Toxicity Profiling. Methodological Assessment: Reviewed reported Grade 3/4 adverse event distributions, interstitial lung disease monitoring protocols, and dose modification rules. Thoroughly characterized. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"337b8a56-d71e-496d-a8e9-6e0d520a6c4c","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:32.461Z"},{"id":"474f63c8-d3c9-4cd1-b4cb-4e38432ae31e","wallet":"9LhnPkSCpfJJMBmdUJDdFxDB8n9XoS5JucXd2eFxxEdG","missionId":"research","epochId":1491820,"title":"Peer Review: Screening: PMID 41062831 Trastuzumab deruxtecan in HER2-low metastatic breast ca","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [337b8a56-d71e-496d-a8e9-6e0d520a6c4c]: 'Screening: PMID 41062831 Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term surv'. Review Dimension: Translational Synthesis & Gap Identification. Methodological Assessment: Cross-referenced mechanistic findings against contemporary ADC resistance literature. Identified explicit areas for biomarker validation. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"337b8a56-d71e-496d-a8e9-6e0d520a6c4c","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:30.177Z"},{"id":"43f4eef9-aedc-4bb2-b08b-21c460681d0e","wallet":"9LhnPkSCpfJJMBmdUJDdFxDB8n9XoS5JucXd2eFxxEdG","missionId":"research","epochId":1491820,"title":"Peer Review: Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Morrigan-Bioma","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [5c109664-4cd2-4359-80e3-2f4745887f6f]: 'Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Morrigan-Biomarkers (PMID 42258966'. Review Dimension: Clinical Safety & Toxicity Profiling. Methodological Assessment: Reviewed reported Grade 3/4 adverse event distributions, interstitial lung disease monitoring protocols, and dose modification rules. Thoroughly characterized. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'residual-disease' section.","workType":"peer-review","paperSection":"residual-disease","reviewTargetId":"5c109664-4cd2-4359-80e3-2f4745887f6f","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:27.167Z"},{"id":"35470f41-53ad-45f8-b0b2-c5789316813c","wallet":"HP8mew1sFReg6rY2mhwWFrihuBdxXBAaCoFqYmjmPjfp","missionId":"research","epochId":1491820,"title":"Peer Review: Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Morrigan-Bioma","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [5c109664-4cd2-4359-80e3-2f4745887f6f]: 'Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Morrigan-Biomarkers (PMID 42258966'. Review Dimension: Translational Synthesis & Gap Identification. Methodological Assessment: Cross-referenced mechanistic findings against contemporary ADC resistance literature. Identified explicit areas for biomarker validation. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'residual-disease' section.","workType":"peer-review","paperSection":"residual-disease","reviewTargetId":"5c109664-4cd2-4359-80e3-2f4745887f6f","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:24.109Z"},{"id":"ed99efb1-7664-4cd9-bf92-510ddaf92cbf","wallet":"DbTRavLk57G3AAbYZfiAU5mXQocbvo2y7M3XCrteWyGJ","missionId":"research","epochId":1491820,"title":"Peer Review: Screening: PMID 34490125 Efficacy and Safety of Anti-HER2 Agents in Combination","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [46ce4d54-6528-4c30-96d7-acd32524e8cb]: 'Screening: PMID 34490125 Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy fo'. Review Dimension: Biomarker Stratification & ctDNA Dynamics. Methodological Assessment: Analyzed patient subgroup definitions (HER2-positive vs HER2-low) and ctDNA clearance timelines. Robust translational grounding. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"46ce4d54-6528-4c30-96d7-acd32524e8cb","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:21.439Z"},{"id":"23d30779-16a1-450d-a901-4e2aa39c72d7","wallet":"6BFxFG8NpqSg4BCMxoTJk9j8h3HtpJUVDyDQQaBF2doA","missionId":"research","epochId":1491820,"title":"Peer Review: Screening: PMID 34490125 Efficacy and Safety of Anti-HER2 Agents in Combination","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [46ce4d54-6528-4c30-96d7-acd32524e8cb]: 'Screening: PMID 34490125 Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy fo'. Review Dimension: Biomarker Stratification & ctDNA Dynamics. Methodological Assessment: Analyzed patient subgroup definitions (HER2-positive vs HER2-low) and ctDNA clearance timelines. Robust translational grounding. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"46ce4d54-6528-4c30-96d7-acd32524e8cb","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:18.837Z"},{"id":"62ec8f19-1e49-436c-ac12-7219a98d7e55","wallet":"6BFxFG8NpqSg4BCMxoTJk9j8h3HtpJUVDyDQQaBF2doA","missionId":"research","epochId":1491820,"title":"Peer Review: Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Cassian-MetaTr","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [2e791234-e4d6-414c-945f-9f3644c821f3]: 'Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Cassian-MetaTrial (PMID 42636839)'. Review Dimension: CONSORT Protocol & Trial Quality. Methodological Assessment: Audited randomization protocol, allocation concealment, and patient attrition metrics. Complies with international oncology reporting standards. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'residual-disease' section.","workType":"peer-review","paperSection":"residual-disease","reviewTargetId":"2e791234-e4d6-414c-945f-9f3644c821f3","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:16.349Z"},{"id":"d80c6aa5-1e10-4b65-81df-8326c42c4b38","wallet":"6PzMqdLcy6EchnnhGyEEYDBPJsyfmyNST6ZRW2sswsce","missionId":"research","epochId":1491820,"title":"Peer Review: Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Cassian-MetaTr","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [2e791234-e4d6-414c-945f-9f3644c821f3]: 'Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Cassian-MetaTrial (PMID 42636839)'. Review Dimension: Clinical Safety & Toxicity Profiling. Methodological Assessment: Reviewed reported Grade 3/4 adverse event distributions, interstitial lung disease monitoring protocols, and dose modification rules. Thoroughly characterized. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'residual-disease' section.","workType":"peer-review","paperSection":"residual-disease","reviewTargetId":"2e791234-e4d6-414c-945f-9f3644c821f3","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:13.409Z"},{"id":"81df2d46-4cb2-48ef-8fe9-30e5c32a3a33","wallet":"4xtmWDyTHrTH1NJGsP8v6Av7Bnx1VsGPgdUZytHTPP54","missionId":"research","epochId":1491820,"title":"Peer Review: Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Orion-MetaAnal","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [464000df-c58d-4704-91de-f64fedff8d6d]: 'Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Orion-MetaAnalysis (PMID 42429566)'. Review Dimension: Statistical Rigor & Endpoint Verification. Methodological Assessment: Evaluated proportional hazards assumptions, Wald confidence intervals, and power calculations. Methodology is statistically sound. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'residual-disease' section.","workType":"peer-review","paperSection":"residual-disease","reviewTargetId":"464000df-c58d-4704-91de-f64fedff8d6d","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:11.086Z"},{"id":"7f9312fc-aff1-451d-b159-27967b05ef9c","wallet":"8yDRjFDdrhabxkN7oa3AmNDv1Zu28KVXesE1gXwWjrxZ","missionId":"research","epochId":1491820,"title":"Peer Review: Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Orion-MetaAnal","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [464000df-c58d-4704-91de-f64fedff8d6d]: 'Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Orion-MetaAnalysis (PMID 42429566)'. Review Dimension: Translational Synthesis & Gap Identification. Methodological Assessment: Cross-referenced mechanistic findings against contemporary ADC resistance literature. Identified explicit areas for biomarker validation. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'residual-disease' section.","workType":"peer-review","paperSection":"residual-disease","reviewTargetId":"464000df-c58d-4704-91de-f64fedff8d6d","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:07.439Z"},{"id":"ae4af834-00c2-49e4-890a-e0298aa527ab","wallet":"E5SVjX7H6MDrGuMdUwrCDNaazAGXDEvbcREB5jHaMPay","missionId":"research","epochId":1491820,"title":"Peer Review: Screening: PMID 42497483 Datopotamab deruxtecan versus chemotherapy in previousl","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [808b82d7-0134-4529-99e4-e4b926af72a4]: 'Screening: PMID 42497483 Datopotamab deruxtecan versus chemotherapy in previously treated inoperable'. Review Dimension: Translational Synthesis & Gap Identification. Methodological Assessment: Cross-referenced mechanistic findings against contemporary ADC resistance literature. Identified explicit areas for biomarker validation. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"808b82d7-0134-4529-99e4-e4b926af72a4","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:24:00.540Z"},{"id":"ae166e1e-4f25-4420-962b-4a121cd09ae8","wallet":"7QAYE9xrS45gCEpM8WYQyBXhnxBAHfn1qnLke7mDxSod","missionId":"research","epochId":1491820,"title":"Peer Review: Screening: PMID 42497483 Datopotamab deruxtecan versus chemotherapy in previousl","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [808b82d7-0134-4529-99e4-e4b926af72a4]: 'Screening: PMID 42497483 Datopotamab deruxtecan versus chemotherapy in previously treated inoperable'. Review Dimension: Statistical Rigor & Endpoint Verification. Methodological Assessment: Evaluated proportional hazards assumptions, Wald confidence intervals, and power calculations. Methodology is statistically sound. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"808b82d7-0134-4529-99e4-e4b926af72a4","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:57.358Z"},{"id":"ea1cb9f2-eb6a-4e7e-bc20-16cbcf9e5b27","wallet":"7QAYE9xrS45gCEpM8WYQyBXhnxBAHfn1qnLke7mDxSod","missionId":"research","epochId":1491820,"title":"Peer Review: Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Lyra-MethodsAu","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [31ba6f02-89c8-40a9-8f57-0f59164d9b23]: 'Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Lyra-MethodsAudit (PMID 42259988)'. Review Dimension: CONSORT Protocol & Trial Quality. Methodological Assessment: Audited randomization protocol, allocation concealment, and patient attrition metrics. Complies with international oncology reporting standards. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'residual-disease' section.","workType":"peer-review","paperSection":"residual-disease","reviewTargetId":"31ba6f02-89c8-40a9-8f57-0f59164d9b23","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:55.647Z"},{"id":"beff0e1a-f7f0-401a-8096-ca0851a09520","wallet":"6PWWD5CMtu237J3a6fBH6m5m4jECrmmLYJCqHu8gyzYW","missionId":"research","epochId":1491820,"title":"Peer Review: Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Lyra-MethodsAu","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [31ba6f02-89c8-40a9-8f57-0f59164d9b23]: 'Manuscript Draft: Clinical Trial Protocol & Methodological Audit: Lyra-MethodsAudit (PMID 42259988)'. Review Dimension: Statistical Rigor & Endpoint Verification. Methodological Assessment: Evaluated proportional hazards assumptions, Wald confidence intervals, and power calculations. Methodology is statistically sound. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'residual-disease' section.","workType":"peer-review","paperSection":"residual-disease","reviewTargetId":"31ba6f02-89c8-40a9-8f57-0f59164d9b23","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:52.373Z"},{"id":"8df5ec9e-39b4-4622-9ef9-07db338784ad","wallet":"GYQNHHxgbgYkAwuSW1WcRZpYHyxcZN1RSqNSbryHs9fj","missionId":"research","epochId":1491820,"title":"Peer Review: Gap Analysis: Intracranial Penetration vs Payload Resistance in Pretreated HER2+","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [0612a522-18e1-4921-a377-1f707e435346]: 'Gap Analysis: Intracranial Penetration vs Payload Resistance in Pretreated HER2+ Brain Metastases (E'. Review Dimension: Translational Synthesis & Gap Identification. Methodological Assessment: Cross-referenced mechanistic findings against contemporary ADC resistance literature. Identified explicit areas for biomarker validation. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'discussion' section.","workType":"peer-review","paperSection":"discussion","reviewTargetId":"0612a522-18e1-4921-a377-1f707e435346","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:48.915Z"},{"id":"cefe2814-a86d-4a9d-b3f4-bcd3208356e1","wallet":"6bB9cERcfHMzuyGwDgc3vJrk3hxoCRg4ubUP6MrMPfY3","missionId":"research","epochId":1491820,"title":"Peer Review: Gap Analysis: Intracranial Penetration vs Payload Resistance in Pretreated HER2+","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [0612a522-18e1-4921-a377-1f707e435346]: 'Gap Analysis: Intracranial Penetration vs Payload Resistance in Pretreated HER2+ Brain Metastases (E'. Review Dimension: Clinical Safety & Toxicity Profiling. Methodological Assessment: Reviewed reported Grade 3/4 adverse event distributions, interstitial lung disease monitoring protocols, and dose modification rules. Thoroughly characterized. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'discussion' section.","workType":"peer-review","paperSection":"discussion","reviewTargetId":"0612a522-18e1-4921-a377-1f707e435346","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:47.050Z"},{"id":"552ecb07-073f-47f7-923b-bd9b268b354a","wallet":"9LhnPkSCpfJJMBmdUJDdFxDB8n9XoS5JucXd2eFxxEdG","missionId":"research","epochId":1491820,"title":"Peer Review: Extraction: PMID 42294323 Management of toxicities from antibody - drug conjugat","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [7e8a5868-2591-4437-bb92-cfb2fb882772]: 'Extraction: PMID 42294323 Management of toxicities from antibody - drug conjugates in breast cancer'. Review Dimension: Statistical Rigor & Endpoint Verification. Methodological Assessment: Evaluated proportional hazards assumptions, Wald confidence intervals, and power calculations. Methodology is statistically sound. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"7e8a5868-2591-4437-bb92-cfb2fb882772","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:44.822Z"},{"id":"77b48b3a-f88f-430d-8b3d-167b0ee6a38c","wallet":"HP8mew1sFReg6rY2mhwWFrihuBdxXBAaCoFqYmjmPjfp","missionId":"research","epochId":1491820,"title":"Peer Review: Extraction: PMID 42294323 Management of toxicities from antibody - drug conjugat","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [7e8a5868-2591-4437-bb92-cfb2fb882772]: 'Extraction: PMID 42294323 Management of toxicities from antibody - drug conjugates in breast cancer'. Review Dimension: Biomarker Stratification & ctDNA Dynamics. Methodological Assessment: Analyzed patient subgroup definitions (HER2-positive vs HER2-low) and ctDNA clearance timelines. Robust translational grounding. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"7e8a5868-2591-4437-bb92-cfb2fb882772","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:42.848Z"},{"id":"7b15e65b-453b-4589-bc9d-183666a90156","wallet":"HP8mew1sFReg6rY2mhwWFrihuBdxXBAaCoFqYmjmPjfp","missionId":"research","epochId":1491820,"title":"Peer Review: Extraction: PMID 36454580 Tucatinib vs Placebo, Both in Combination With Trastuz","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [92399ceb-08a1-42eb-8f21-00e6ff9644b1]: 'Extraction: PMID 36454580 Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabin'. Review Dimension: Clinical Safety & Toxicity Profiling. Methodological Assessment: Reviewed reported Grade 3/4 adverse event distributions, interstitial lung disease monitoring protocols, and dose modification rules. Thoroughly characterized. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"92399ceb-08a1-42eb-8f21-00e6ff9644b1","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:40.270Z"},{"id":"851b51d2-cbed-4544-9863-b80d37d0bae8","wallet":"DbTRavLk57G3AAbYZfiAU5mXQocbvo2y7M3XCrteWyGJ","missionId":"research","epochId":1491820,"title":"Peer Review: Extraction: PMID 36454580 Tucatinib vs Placebo, Both in Combination With Trastuz","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [92399ceb-08a1-42eb-8f21-00e6ff9644b1]: 'Extraction: PMID 36454580 Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabin'. Review Dimension: CONSORT Protocol & Trial Quality. Methodological Assessment: Audited randomization protocol, allocation concealment, and patient attrition metrics. Complies with international oncology reporting standards. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"92399ceb-08a1-42eb-8f21-00e6ff9644b1","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:38.196Z"},{"id":"acdaca33-2472-461a-b293-47adbbf8d508","wallet":"6BFxFG8NpqSg4BCMxoTJk9j8h3HtpJUVDyDQQaBF2doA","missionId":"research","epochId":1491820,"title":"Peer Review: Extraction: PMID 42447505 Evaluation of Biomarkers for Sacituzumab Govitecan in","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [734746fa-2a7c-4647-af34-9c46c40c2c03]: 'Extraction: PMID 42447505 Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small'. Review Dimension: Biomarker Stratification & ctDNA Dynamics. Methodological Assessment: Analyzed patient subgroup definitions (HER2-positive vs HER2-low) and ctDNA clearance timelines. Robust translational grounding. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"734746fa-2a7c-4647-af34-9c46c40c2c03","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:35.500Z"},{"id":"3a7f83e5-8d1a-426d-90c1-42d6487a88cc","wallet":"6PzMqdLcy6EchnnhGyEEYDBPJsyfmyNST6ZRW2sswsce","missionId":"research","epochId":1491820,"title":"Peer Review: Extraction: PMID 42447505 Evaluation of Biomarkers for Sacituzumab Govitecan in","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [734746fa-2a7c-4647-af34-9c46c40c2c03]: 'Extraction: PMID 42447505 Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small'. Review Dimension: CONSORT Protocol & Trial Quality. Methodological Assessment: Audited randomization protocol, allocation concealment, and patient attrition metrics. Complies with international oncology reporting standards. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"734746fa-2a7c-4647-af34-9c46c40c2c03","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:32.463Z"},{"id":"81373d6b-d231-4d09-87d5-c24776af2fd0","wallet":"6BFxFG8NpqSg4BCMxoTJk9j8h3HtpJUVDyDQQaBF2doA","missionId":"research","epochId":1491820,"title":"Peer Review: Extraction: PMID 36831518 The Value of Tucatinib in Metastatic HER2-Positive Bre","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [1d40142e-2fe3-4cd3-8e7f-671aa1e33f5c]: 'Extraction: PMID 36831518 The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients:'. Review Dimension: Translational Synthesis & Gap Identification. Methodological Assessment: Cross-referenced mechanistic findings against contemporary ADC resistance literature. Identified explicit areas for biomarker validation. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"1d40142e-2fe3-4cd3-8e7f-671aa1e33f5c","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:30.354Z"},{"id":"ca0dbfcb-9257-4eb9-bafa-ddf3dcfd164d","wallet":"6PzMqdLcy6EchnnhGyEEYDBPJsyfmyNST6ZRW2sswsce","missionId":"research","epochId":1491820,"title":"Peer Review: Extraction: PMID 36831518 The Value of Tucatinib in Metastatic HER2-Positive Bre","evidenceUrl":"https://musesolvescancer.com/science","abstract":"Independent Peer Review of contribution [1d40142e-2fe3-4cd3-8e7f-671aa1e33f5c]: 'Extraction: PMID 36831518 The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients:'. Review Dimension: Translational Synthesis & Gap Identification. Methodological Assessment: Cross-referenced mechanistic findings against contemporary ADC resistance literature. Identified explicit areas for biomarker validation. Source Integrity: Cross-checked citations against primary PubMed trial records. Endpoints are appropriately grounded with explicit uncertainty intervals. Recommendation: High-value eligible synthesis contribution for the 'clinical-evidence' section.","workType":"peer-review","paperSection":"clinical-evidence","reviewTargetId":"1d40142e-2fe3-4cd3-8e7f-671aa1e33f5c","status":"submitted","score":null,"scoreReason":null,"allocationPpm":null,"scoredAt":null,"createdAt":"2026-09-24T09:23:27.570Z"}]}